Mineralys Therapeutics reported a net loss of $337.7 million for the nine months ended September 30, 2026, driven by a $200 million upfront license amendment payment and increased R&D and G&A expenses. The company ended the period with $624.7 million in cash, cash equivalents, and investments, and is awaiting an FDA decision on its NDA for lorundrostat with a PDUFA date of December 22, 2026.
Mineralys Therapeutics reported Q3 2026 financial results and provided a corporate update regarding its lead candidate, lorundrostat, which has a PDUFA target date of December 22, 2026. The company also announced the resignation of board member Derek DiRocco, Ph.D., effective December 31, 2026.
“With approximately 20 million adults in the U.S. living with uncontrolled or resistant hypertension, despite treatment, there is a significant need for new treatment options. As we approach the December 22nd PDUFA target date for lorundrostat, our focus is on completing our launch preparations so that we are ready to reach patients quickly, pending approval.”
Jon Congleton, Chief Executive Officer of Mineralys
“We continue to receive positive feedback from providers, payers and people living with hypertension, and we look forward to the potential to bring lorundrostat to millions of patients in need.”
Jon Congleton, Chief Executive Officer of Mineralys
Mineralys Therapeutics M&A Deal with Tanabe Pharma Corporation
Mineralys Therapeutics entered into a Termination Agreement and Payment Obligation Agreement with Tanabe Pharma Corporation to acquire full ownership of the intellectual property for lorundrostat. The agreements terminate the existing license and assign the patents and know-how directly to Mineralys, while maintaining existing commercial milestone obligations of up to $265 million. This transition from licensee to owner removes potential change-of-control payment triggers and consolidates the company's control over its lead drug candidate.
Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors, effective October 19, 2026, increasing the board size from seven to nine members. Both new directors will receive standard non-employee director compensation, including initial grants of 16,600 stock options and 12,400 restricted stock units each.